Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
J Clin Oncol
; 9(11): 2021-6, 1991 Nov.
Article
em En
| MEDLINE
| ID: mdl-1941061
ABSTRACT
Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dose levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Hemoglobinas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Eritropoetina
/
Anemia
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1991
Tipo de documento:
Article